SPOTLIGHT -
From the Editor: PARP Inhibitors, Biomarker Research, and Gene Editing
Our physician editor-in-chief highlights the February 2015 issue of The Journal of Targeted Therapies in Cancer.
MEK Inhibitors
The RAS-RAF-MEK-extracellular signal–regulated kinase 1 and 2 (ERK1/2) pathway is the most mutated pathway in human cancer. Thus, components of this pathway have been seen as promising targets for cancer therapy.
MEK Inhibitors for the Treatment of Melanoma
Alex A. Adjei, MD, PhD, discusses the use of MEK inhibitors when treating patients with melanoma.
